Responses
Regular and young investigator award abstracts
Clinical trials in progress
422 An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts
Compose a Response to This Article
Other responses
No responses have been published for this article.